Marc Fisher, MD

5407 Junction Blvd



Stroke: While Current Treatment Is Limited, New Options Are on the Horizon

January 21, 2005

Current therapy for acute ischemic stroke remains limited to intravenous recombinant tissue plasminogen activator (tPA) administered within 3 hours of symptom onset, but despite strong evidence supporting its effectiveness,1-5 only 2% to 4% of all stroke patients currently receive tPA.